SG10201600854SA - Compostions And Methods For Treating Chronic Inflammation And Inflammatory Diseases - Google Patents

Compostions And Methods For Treating Chronic Inflammation And Inflammatory Diseases

Info

Publication number
SG10201600854SA
SG10201600854SA SG10201600854SA SG10201600854SA SG10201600854SA SG 10201600854S A SG10201600854S A SG 10201600854SA SG 10201600854S A SG10201600854S A SG 10201600854SA SG 10201600854S A SG10201600854S A SG 10201600854SA SG 10201600854S A SG10201600854S A SG 10201600854SA
Authority
SG
Singapore
Prior art keywords
compostions
methods
inflammatory diseases
chronic inflammation
treating chronic
Prior art date
Application number
SG10201600854SA
Inventor
Robin Mark Bannister
John Brew
Wilson Caparros-Wanderley
Gregory Alan Stoloff
Suzanne Jane Dilly
Gemma Szucs
Mateo Olga Pleguezuelos
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1101937.9A external-priority patent/GB201101937D0/en
Priority claimed from GBGB1113730.4A external-priority patent/GB201113730D0/en
Priority claimed from GBGB1113729.6A external-priority patent/GB201113729D0/en
Priority claimed from GB1113728.8A external-priority patent/GB2487808A/en
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of SG10201600854SA publication Critical patent/SG10201600854SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201600854SA 2011-02-04 2012-02-03 Compostions And Methods For Treating Chronic Inflammation And Inflammatory Diseases SG10201600854SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1101937.9A GB201101937D0 (en) 2011-02-04 2011-02-04 Method of preparing a composition
GBGB1113730.4A GB201113730D0 (en) 2011-08-10 2011-08-10 Solid dosage form
GBGB1113729.6A GB201113729D0 (en) 2011-08-10 2011-08-10 Hyperlipidaemia
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease

Publications (1)

Publication Number Publication Date
SG10201600854SA true SG10201600854SA (en) 2016-03-30

Family

ID=46602107

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201600854SA SG10201600854SA (en) 2011-02-04 2012-02-03 Compostions And Methods For Treating Chronic Inflammation And Inflammatory Diseases
SG2013059365A SG192621A1 (en) 2011-02-04 2012-02-03 Compositions and methods for treating cardiovascular diseases
SG2013059357A SG192620A1 (en) 2011-02-04 2012-02-03 Compostions and methods for treating chronic inflammation and inflammatory diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2013059365A SG192621A1 (en) 2011-02-04 2012-02-03 Compositions and methods for treating cardiovascular diseases
SG2013059357A SG192620A1 (en) 2011-02-04 2012-02-03 Compostions and methods for treating chronic inflammation and inflammatory diseases

Country Status (11)

Country Link
EP (3) EP2670389A1 (en)
JP (3) JP2014504629A (en)
CN (2) CN103391768B (en)
AU (2) AU2012213218C1 (en)
BR (2) BR112013019732B1 (en)
CA (2) CA2826506C (en)
MX (2) MX346224B (en)
RU (3) RU2635188C2 (en)
SG (3) SG10201600854SA (en)
WO (2) WO2012104655A2 (en)
ZA (2) ZA201305783B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687019B1 (en) * 2003-11-20 2017-11-22 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
TW201347754A (en) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc Compositions of statins and omega-3 fatty acids
EP2911659A2 (en) 2012-10-24 2015-09-02 Biocopea Limited Drug combinations and uses
JP6389190B2 (en) * 2013-01-14 2018-09-12 インファースト ヘルスケア リミテッド Solid solution composition and use in chronic inflammation
CN104968330A (en) * 2013-01-14 2015-10-07 因佛斯特医疗有限公司 Compositions and methods for treating severe pain
CA2898113C (en) 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
RU2680801C2 (en) * 2013-02-04 2019-02-27 ИнФерст Хэлткэр Лимитед Compositions and methods of treating chronic inflammation and inflammatory diseases
KR101344218B1 (en) * 2013-05-15 2013-12-20 충남대학교산학협력단 Pharmaceutical composition for treatment of tuberculosis containing fenofibrate
RU2623876C2 (en) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Pharmaceutical composition for hyperlipidemia treatment
KR101512606B1 (en) 2014-12-11 2015-04-15 (주)이지코스 Cosmetic composition for improving wrinkle and atopic dermatitis and moisturizing
CN105853405B (en) * 2015-01-23 2019-03-08 中国科学院上海药物研究所 Benzbromarone is preparing the application in voltage gated k+ channel blocker KCNQ agonist
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
KR20180021735A (en) * 2015-06-15 2018-03-05 바이탈 쎄러피스, 인코포레이티드 Compositions and methods for inducing anti-inflammatory responses
CN105294672A (en) * 2015-12-07 2016-02-03 范秀华 Pharmaceutical composition for treating endometritis
CN105753826A (en) * 2016-05-09 2016-07-13 宋晓梅 Medicinal composition of gemfibrozil and medicinal application of medicinal composition
CN106074500A (en) * 2016-07-08 2016-11-09 重庆医药高等专科学校 The application in preparation inflammatory enteropathy medicine of the dehydrogenation lovastatin
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US20180125795A1 (en) * 2017-01-03 2018-05-10 Thermolife International, Llc Cinnamaldehyde compositions and methods
JP6784973B2 (en) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 Single-walled carbon nanotubes
WO2018230751A1 (en) * 2017-06-14 2018-12-20 주식회사 바이오솔루션 Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p
AU2017424129B2 (en) * 2017-07-18 2021-12-09 Deyi Pharmarmaceutical Ltd. Application of cannabidiol in treatment of pulmonary hypertension
CN114767646A (en) * 2017-07-19 2022-07-22 铁木医药有限公司 Effects of gastric retentive bile acid sequestrant formulation
KR20200044016A (en) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 GLP-1 composition and use
WO2019041239A1 (en) * 2017-08-31 2019-03-07 汉义生物科技（北京）有限公司 Uses of cannabidiol in preparation of drugs for resisting against influenza
CN109419786B (en) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 Application of cannabidiol in preparation of anti-influenza drugs
CN111587110A (en) * 2018-01-12 2020-08-25 麦提麦迪制药有限公司 Method for treating chronic inflammatory diseases
ES2941777T3 (en) * 2018-06-03 2023-05-25 Chen Wen Pin Method for the treatment of non-compaction cardiomyopathy
WO2020061687A1 (en) * 2018-09-28 2020-04-02 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
CN109846885A (en) * 2019-04-04 2019-06-07 南通大学附属医院 The new application of Rosuvastatin
AU2020401838A1 (en) * 2019-12-11 2022-07-21 Ambetex Pty Ltd Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
RU2749857C1 (en) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Method for combatting otitis media and otitis externa
BR112022013795A2 (en) 2020-02-18 2022-09-13 Novo Nordisk As LIQUID PHARMACEUTICAL COMPOSITION AND KIT
JPWO2021215409A1 (en) 2020-04-20 2021-10-28
RU2745687C1 (en) * 2020-05-19 2021-03-30 Всеволод Иванович Киселев Method for treating endometriosis with pain syndrome and pharmaceutical composition for its implementation
CN112007165B (en) * 2020-08-27 2021-10-08 北京大学人民医院 Macrophage polarization regulator and application thereof in promoting thrombopoiesis
CN112156089A (en) * 2020-09-27 2021-01-01 天津国际生物医药联合研究院 Application of benzbromarone in resisting mycobacterium tuberculosis infection
WO2023058975A1 (en) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 Pharmaceutical composition for inhibiting hsp47 including benzofuranyl hydroxyphenyl methanone derivative
WO2023244738A1 (en) * 2022-06-15 2023-12-21 The Johns Hopkins University Thiazolidinediones for the treatment of muscular dystrophies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
IT1255007B (en) * 1991-07-01 1995-10-11 Altergon Sa SOLUBLE SALTS OF IBUPROFEN C0N N- (2-HYDROXYETHYL) PYROLIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU4021100A (en) * 1999-03-31 2000-10-16 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU2001297778B2 (en) * 2000-12-19 2007-05-31 The Board Of Regents Of The University Of Texas System NSAID formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
JP2005068060A (en) * 2003-08-22 2005-03-17 Nrl Pharma Inc Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin
CN100486567C (en) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 Curcumin emulsion and its preparation process
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
WO2008144355A2 (en) * 2007-05-17 2008-11-27 Morton Grove Pharmaceuticals, Inc. Stable, self-microemulsifying fenofibrate compositions
US20090162442A1 (en) * 2007-09-07 2009-06-25 Shenoy Dinesh B Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin
RU2363451C2 (en) * 2007-09-14 2009-08-10 Общество С Ограниченной Ответственностью "Технология Лекарств" Composition for making dosage form with prolonged effect and method of making said form
EP2310371B1 (en) 2008-05-26 2013-05-15 Genfit Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
CN101926757B (en) * 2010-09-01 2013-01-02 北京大学 Liquid composition of indissolvable medicines and preparation method thereof

Also Published As

Publication number Publication date
EP2670389A1 (en) 2013-12-11
MX364229B (en) 2019-04-17
AU2012213218C1 (en) 2017-04-20
AU2012213218A1 (en) 2013-08-15
WO2012104655A2 (en) 2012-08-09
WO2012104654A1 (en) 2012-08-09
EP2670390A2 (en) 2013-12-11
AU2012213218B9 (en) 2017-02-02
AU2012213217B2 (en) 2017-04-20
AU2012213218B2 (en) 2017-01-12
CA2826506A1 (en) 2012-08-09
MX2013008851A (en) 2013-12-16
MX2013008850A (en) 2016-09-23
CA2826452A1 (en) 2012-08-09
BR112013019734A2 (en) 2016-10-25
CN103391768B (en) 2016-08-10
SG192620A1 (en) 2013-09-30
CN103391768A (en) 2013-11-13
CA2826506C (en) 2017-07-25
RU2635188C2 (en) 2017-11-09
CA2826452C (en) 2016-11-22
ZA201305783B (en) 2014-04-30
CN103391767A (en) 2013-11-13
BR112013019732B1 (en) 2023-01-24
EP3494961A1 (en) 2019-06-12
NZ711187A (en) 2016-01-29
NZ613805A (en) 2016-01-29
JP6273304B2 (en) 2018-01-31
RU2013140775A (en) 2015-03-10
MX346224B (en) 2017-03-10
JP2016128482A (en) 2016-07-14
SG192621A1 (en) 2013-09-30
WO2012104655A3 (en) 2013-03-14
JP2014504629A (en) 2014-02-24
RU2016138830A (en) 2018-12-12
ZA201305784B (en) 2014-04-30
RU2013140776A (en) 2015-03-10
AU2012213217A1 (en) 2013-08-15
EP3494961B1 (en) 2024-04-10
CN103391767B (en) 2016-08-31
JP2014507429A (en) 2014-03-27
BR112013019732A2 (en) 2016-10-25
NZ613812A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
SG10201600854SA (en) Compostions And Methods For Treating Chronic Inflammation And Inflammatory Diseases
HK1218621A1 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
IL269166A (en) Methods and compositions for treating inflammation
EP2684167A4 (en) Compositions and methods useful for treating diseases
HK1199015A1 (en) Treatment of inflammation
EP2763540A4 (en) Compositions and methods for assessing and treating inflammatory diseases and disorders
EP2723347A4 (en) Prevention and treatment of inflammatory conditions
EP2731597A4 (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
EP2544703A4 (en) Methods of treating vascular inflammatory disorders
HK1202248A1 (en) Compositions and methods for treating neurodegenerative disease
IL232190A0 (en) Methods of treating inflammatory disorders using anti-m-csf antibodies
HK1202246A1 (en) Compositions and methods for treating neurodegenerative disease
EP2688402A4 (en) Methods for treating or preventing urological inflammation
PL2773325T3 (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
EP2849778A4 (en) Method for treating inflammation
HK1203430A1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
EP2970510A4 (en) Methods and compositions for treating cancer and inflammatory diseases
EP2780360A4 (en) Compositions and methods for treating autoimmune and inflammatory disorders
HK1202420A1 (en) Methods for treating psoriasis and vascular inflammation
EP2928460A4 (en) Methods for preventing and treating inflammatory skin conditions
EP2673372A4 (en) Methods of prognosing and administering treatment for inflammatory disorders
EP2600864A4 (en) Compositions and methods for treating inflammatory diseases
EP2718427A4 (en) Compositions and methods for glioblastoma treatment
GB201100651D0 (en) Treatment of inflammation
IL227921A0 (en) Methods of prognosing and administering treatment for inflammatory disorders